Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Halberd Corp
(OP:
HALB
)
0.0080
-0.0002 (-2.44%)
Streaming Delayed Price
Updated: 2:20 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halberd Corp
< Previous
1
2
3
4
5
Next >
NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology
August 04, 2022
Via
ACCESSWIRE
Halberd Corporation Discusses OTCQB Uplisting and Growing List of Proprietary Technologies with The Stock Day Podcast
July 28, 2022
Phoenix, Arizona--(Newsfile Corp. - July 28, 2022) - The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB), a publicly...
Via
Newsfile
Topics
Intellectual Property
Exposures
Intellectual Property
Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary
July 20, 2022
Via
ACCESSWIRE
Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary
July 20, 2022
JACKSON CENTER, PA / ACCESSWIRE / July 20, 2022 / Halberd Corporation (OTC PINK:HALB) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd's patented...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Halberd's Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron
July 14, 2022
Boosts Effectiveness of Commercial Covid Antibodies by 45%
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Halberd Corporation Update, CEO Letter and 2022 Expectations
July 12, 2022
Q2 Accomplishments and a Look to the Future
From
Halberd Corporation
Via
AccessWire
Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer
June 21, 2022
JACKSON CENTER, PA / ACCESSWIRE / June 21, 2022 / Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC PINK:HALB) announced the creation of...
From
Halberd Corporation
Via
AccessWire
Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification
June 08, 2022
JACKSON CENTER, PA / ACCESSWIRE / June 8, 2022 / Halberd Corporation (OTC PINK:HALB) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the...
From
Halberd Corporation
Via
AccessWire
Topics
Animal Testing
Exposures
Animal Testing
Product Safety
Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines
May 24, 2022
JACKSON CENTER, PA / ACCESSWIRE / May 24, 2022 / Halberd Corporation (OTC PINK:HALB) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted...
From
Halberd Corporation
Via
AccessWire
Topics
Animal Testing
Exposures
Animal Testing
Product Safety
Halberd Engages Professional Firm to Proceed with FDA Filings
May 18, 2022
JACKSON CENTER, PA / ACCESSWIRE / May 18, 2022 / Halberd Corporation (OTC PINK:HALB) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the U.S. Food and Drug...
From
Halberd Corporation
Via
AccessWire
Exposures
Product Safety
Halberd Submits Audited Financials; Files Form-10 as First Step to Up-list to OTCQB
May 12, 2022
JACKSON CENTER, PA / ACCESSWIRE / May 12, 2022 / Halberd Corporation (OTC PINK:HALB) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step...
From
Halberd Corporation
Via
AccessWire
Topics
Animal Testing
Regulatory Compliance
Exposures
Animal Testing
Legal
Product Safety
Dr. Gregg Sturrus' TEDx Talk(R) Features Halberd's Extracorporeal Treatment of Neurodegenerative Diseases
April 29, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Halberd Corporation
Via
AccessWire
Halberd CEO Letter
April 25, 2022
Q1 Accomplishments and Q2 Plans JACKSON CENTER, PA / ACCESSWIRE / April 25, 2022 / Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC PINK:HALB) This past quarter has witnessed some very...
From
Halberd Corporation
Via
AccessWire
Halberd Eliminates E. Coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics
April 18, 2022
JACKSON CENTER, PA / ACCESSWIRE / April 18, 2022 / Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease...
From
Halberd Corporation
Via
AccessWire
Topics
Animal Testing
Exposures
Animal Testing
Halberd Entering the Medical Metaverse(TM)
April 11, 2022
JACKSON CENTER, PA / ACCESSWIRE / April 11, 2022 / Halberd Corporation (OTC PINK:HALB) announces plans to enter the Metaverse by the creation of non-fungible tokens (NFT's) to monetize certain...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression
April 04, 2022
JACKSON CENTER, PA / ACCESSWIRE / April 4, 2022 / Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to...
From
Halberd Corporation
Via
AccessWire
Infectious Disease Specialist Will Guide Halberd's Extracorporeal Elimination of Disease Antigens in Animals and Then Humans
March 16, 2022
JACKSON CENTER, PA / ACCESSWIRE / March 16, 2022 / Halberd Corporation (OTC PINK:HALB) announces its entry into the next stage of research. To guide it, having successfully eliminated the Top 10 Target...
From
Halberd Corporation
Via
AccessWire
Halberd Expands Its Technical Expertise with the Addition of Microbiology Professor
March 08, 2022
JACKSON CENTER, PA / ACCESSWIRE / March 8, 2022 / Halberd Corporation (OTC PINK:HALB) is pleased to announce Youngstown State University's (YSU) Dr. Chester R. Cooper has joined its technical team. Dr....
From
Halberd Corporation
Via
AccessWire
Halberd's COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant
March 01, 2022
Outperforms Approved COVID Antibodies JACKSON CENTER, PA / ACCESSWIRE / March 1, 2022 / Halberd Corporation's (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding...
From
Halberd Corporation
Via
AccessWire
Exposures
COVID-19
Product Safety
Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually
February 22, 2022
JACKSON CENTER, PA / ACCESSWIRE / February 22, 2022 / Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination...
From
Halberd Corporation
Via
AccessWire
Halberd Eliminates 100% of Tau Protein From CSF - The 9th of 10 Target Neurodegenerative Disease Antigens
February 08, 2022
Tau buildup in the brain is linked to Alzheimer's and other neurodegenerative diseases. JACKSON CENTER, PA / ACCESSWIRE / February 8, 2022 / Halberd Corporation (OTC PINK:HALB) has demonstrated the...
From
Halberd Corporation
Via
AccessWire
Halberd Achieves Landmark Selective Elimination of Tau From an Antigen Mixture
February 01, 2022
Tau has been shown to be important in the development of Alzheimer's Disease. Eradication of Tau accomplished without reducing levels of non-target cytokine. JACKSON CENTER, PA / ACCESSWIRE / February...
From
Halberd Corporation
Via
AccessWire
Halberd CEO Letter: 2021 Year-End & 2022 Outlook
January 25, 2022
JACKSON CENTER, PA / ACCESSWIRE / January 25, 2022 / Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC PINK:HALB) First of all I want to wish all of our shareholders and constituents a Very...
From
Halberd Corporation
Via
AccessWire
Halberd, Inc. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases
January 13, 2022
JACKSON CENTER, PA / ACCESSWIRE / January 13, 2022 / Halberd, Inc. (OTC PINK:HALB) ("HALB" or the "Company"), an innovative biotech company focused on developing treatments for difficult-to-cure...
From
Halberd Corporation
Via
AccessWire
Halberd Corporation Now an Official US Government Contractor
January 05, 2022
Halberd to bid on Additional Federal Contracts with the Federal Government JACKSON CENTER, PA / ACCESSWIRE / January 5, 2022 / Halberd Corporation (OTC PINK:HALB) is now registered with the Federal...
From
Halberd Corporation
Via
AccessWire
Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases
December 20, 2021
Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid JACKSON CENTER, PA / ACCESSWIRE / December 20, 2021 / Halberd Corporation (OTC Pink:HALB) has been able to successfully eliminate...
From
Halberd Corporation
Via
AccessWire
Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases
December 15, 2021
JACKSON CENTER, PA / ACCESSWIRE / December 15, 2021 / Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid (CSF) in...
From
Halberd Corporation
Via
AccessWire
Halberd Successfully Eradicates Interleukin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases
December 13, 2021
JACKSON CENTER, PA / ACCESSWIRE / December 13, 2021 / Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer's Disease and PTSD/CTE
December 06, 2021
JACKSON CENTER, PA / ACCESSWIRE / December 6, 2021 / Halberd Corporation (OTC PINK:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Halberd Successfully Eradicates TNF-a, a Major Contributing Factor to Alzheimer’s Disease
November 22, 2021
JACKSON CENTER, PA / ACCESSWIRE / November 22, 2021 / Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF)...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.